476
Participants
Start Date
March 10, 2020
Primary Completion Date
November 9, 2021
Study Completion Date
November 9, 2021
Canagliflozin 100 mg
Participants will receive 100 mg immediate-release, over-encapsulated tablets (as a capsule) orally once daily.
Placebo
Participants will receive matching placebo capsules orally once daily.
MedStar Health Research Institute, Hyattsville
Emory University, Atlanta
Clearwater Cardiovascular Consultants, Clearwater
University Hospitals Cleveland Medical Center, Cleveland
Parkview Cancer Institute, Fort Wayne
University of Michigan, Ann Arbor
Henry Ford Hospital, Detroit
Central Dupage Hospital, Winfield
OSF HealthCare Cardiovascular Institute, Peoria
Mercy Health Research, Washington
St. Luke's Hospital Kansas City, Kansas City
University of Kansas Medical Center Research Institute, Kansas City
Mercy Clinic Cardiology - Fort Smith, Fort Smith
Texas Heart Institute, Houston
Thomas Spann Clinic, Corpus Christi
University of Colorado Anschutz Medical Campus, Aurora
St Lukes Regional Medical, Boise
Robert Wood Johnson Medical School Dept. of Medicine, Piscataway
Janssen Research & Development, LLC
INDUSTRY